Health Care • Biotechnology: Pharmaceutical Preparations
$1.73 ▼ -0.01
(-0.57%)
MKT CAP: $29.3M • VOL: 40.8K
52W L $2 52W H $13
ROARABLE / RQD
D- • 37/100
PIOTROSKI
2 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$1
MEDIAN
$2
MEAN
$2
HIGH
$2
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE RNAZ TAPE
RNAZ // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $2.09 | $1.99 | 2025-02-14 | $1.57 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $2.18 | $2.04 | 2025-02-06 | $1.63 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $1.97 | $1.90 | 2025-01-29 | $1.66 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $1.76 | — | 2025-01-17 | $1.70 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $1.52 | $1.64 | 2025-01-09 | $1.54 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $2.06 | $1.80 | 2024-12-18 | $1.51 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $1.68 | $1.75 | 2024-12-04 | $1.61 | -4.3% | 48% | C |